Fernando Bril

8.0k total citations · 6 hit papers
85 papers, 5.6k citations indexed

About

Fernando Bril is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Hepatology. According to data from OpenAlex, Fernando Bril has authored 85 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Epidemiology, 43 papers in Endocrinology, Diabetes and Metabolism and 21 papers in Hepatology. Recurrent topics in Fernando Bril's work include Liver Disease Diagnosis and Treatment (66 papers), Diet, Metabolism, and Disease (38 papers) and Pancreatitis Pathology and Treatment (14 papers). Fernando Bril is often cited by papers focused on Liver Disease Diagnosis and Treatment (66 papers), Diet, Metabolism, and Disease (38 papers) and Pancreatitis Pathology and Treatment (14 papers). Fernando Bril collaborates with scholars based in United States, Argentina and France. Fernando Bril's co-authors include Kenneth Cusi, Romina Lomonaco, Beverly Orsak, Fermin O. Tio, Joan Hecht, Paola Portillo-Sánchez, Nishanth E. Sunny, Amy Webb, Srilaxmi Kalavalapalli and Diane Biernacki and has published in prestigious journals such as Annals of Internal Medicine, PLoS ONE and Hepatology.

In The Last Decade

Fernando Bril

83 papers receiving 5.5k citations

Hit Papers

Long-Term Pioglitazone Treatment for Patients With Nonalc... 2015 2026 2018 2022 2016 2018 2015 2019 2020 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus
    2016 737 citations Kenneth Cusi, Beverly Orsak et al. Annals of Internal Medicine profile →
  2. Modulation of Insulin Resistance in Nonalcoholic Fatty Liver Disease
    2018 405 citations Fernando Bril, Kenneth Cusi et al. profile →
  3. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels
    2015 393 citations Paola Portillo-Sánchez, Fernando Bril et al. The Journal of Clinical Endocrinology & Metabolism profile →
  4. Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial
    2019 235 citations Fernando Bril, Diane Biernacki et al. Diabetes Care profile →
  5. Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening
    2020 231 citations Romina Lomonaco, Eddison Godinez Leiva et al. Diabetes Care profile →
  6. Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD
    2025 32 citations Diana Barb, Srilaxmi Kalavalapalli et al. Journal of Hepatology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fernando Bril United States 33 4.8k 2.9k 1.5k 1.1k 961 85 5.6k
James M. Paik United States 34 5.5k 1.2× 2.5k 0.9× 2.3k 1.5× 778 0.7× 877 0.9× 84 6.4k
Stefano Ballestri Italy 32 4.5k 0.9× 2.3k 0.8× 1.6k 1.1× 734 0.7× 637 0.7× 54 5.3k
Shivakumar Chitturi Australia 25 4.4k 0.9× 2.1k 0.7× 1.5k 1.0× 766 0.7× 745 0.8× 40 5.5k
Romina Lomonaco United States 25 3.6k 0.8× 2.2k 0.8× 1.1k 0.8× 710 0.6× 734 0.8× 37 4.2k
Fabio Nascimbeni Italy 28 4.1k 0.9× 2.2k 0.8× 1.5k 1.0× 594 0.5× 563 0.6× 54 4.8k
M. Marietti Italy 8 4.0k 0.8× 1.6k 0.6× 1.5k 1.0× 975 0.9× 595 0.6× 17 4.6k
Aynur Ünalp United States 17 4.1k 0.8× 2.1k 0.7× 1.7k 1.1× 702 0.6× 673 0.7× 32 4.6k
Dinan Abdelatif United States 5 7.0k 1.5× 2.9k 1.0× 2.9k 2.0× 1.2k 1.1× 980 1.0× 10 7.8k
Ester Vanni Italy 25 7.0k 1.5× 3.5k 1.2× 2.4k 1.6× 961 0.9× 1.1k 1.1× 34 7.9k
Stefania Natale Italy 5 4.5k 0.9× 2.6k 0.9× 1.0k 0.7× 810 0.7× 756 0.8× 8 5.1k

Countries citing papers authored by Fernando Bril

Since Specialization
Citations

This map shows the geographic impact of Fernando Bril's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fernando Bril with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fernando Bril more than expected).

Fields of papers citing papers by Fernando Bril

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fernando Bril. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fernando Bril. The network helps show where Fernando Bril may publish in the future.

Co-authorship network of co-authors of Fernando Bril

This figure shows the co-authorship network connecting the top 25 collaborators of Fernando Bril. A scholar is included among the top collaborators of Fernando Bril based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fernando Bril. Fernando Bril is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bril, Fernando, et al.. (2025). Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Journal of Lipid and Atherosclerosis. 14(1). 5–5. 2 indexed citations
2.
Azziz, Ricardo, Mina Amiri, Fernando Bril, et al.. (2025). Approach to the Patient: Hirsutism. The Journal of Clinical Endocrinology & Metabolism. 110(10). e3503–e3519. 1 indexed citations
3.
Barb, Diana, Srilaxmi Kalavalapalli, Eddison Godinez Leiva, et al.. (2025). Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD. Journal of Hepatology. 82(6). 979–991. 32 indexed citations breakdown →
4.
Bril, Fernando, et al.. (2025). Role of Hepatic Glycogen on Nocturnal Gluconeogenesis in Type 2 Diabetes Mellitus. The Journal of Clinical Endocrinology & Metabolism. 110(10). 2790–2799. 1 indexed citations
5.
Campbell, Elizabeth A., et al.. (2025). Risk of Euglycemic Diabetic Ketoacidosis Can Persist After Discontinuation of Sodium-glucose Cotransporter-2 Inhibitors. JCEM Case Reports. 3(12). luaf268–luaf268.
6.
Bril, Fernando, et al.. (2024). EVALUATING CHATGPT’S RESPONSES TO FREQUENTLY ASKED QUESTIONS REGARDING POLYCYSTIC OVARY SYNDROME. Fertility and Sterility. 122(1). e55–e55. 1 indexed citations
7.
Sharma, Anu, Eddison Godinez Leiva, Srilaxmi Kalavalapalli, et al.. (2024). Obesity increases the risk of hepatic fibrosis in young adults with type 2 diabetes mellitus: the need to screen. Obesity. 32(10). 1967–1974. 9 indexed citations
8.
Bril, Fernando, Srilaxmi Kalavalapalli, Romina Lomonaco, et al.. (2024). Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants. JHEP Reports. 6(7). 101092–101092. 17 indexed citations
9.
Markovic, Daniela, et al.. (2024). Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome. The Journal of Clinical Endocrinology & Metabolism. 110(1). e168–e176. 2 indexed citations
10.
11.
Gastaldelli, Amalia, Silvia Sabatini, Fabrizia Carli, et al.. (2021). PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH. Liver International. 41(11). 2659–2670. 74 indexed citations
12.
Lomonaco, Romina, Eddison Godinez Leiva, Fernando Bril, et al.. (2020). Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care. 44(2). 399–406. 231 indexed citations breakdown →
13.
Bril, Fernando, et al.. (2019). Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 104(8). 3327–3336. 74 indexed citations
14.
Bril, Fernando, Diane Biernacki, Srilaxmi Kalavalapalli, et al.. (2019). Role of Vitamin E for Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized Controlled Trial. Diabetes Care. 42(8). 1481–1488. 235 indexed citations breakdown →
15.
Bril, Fernando, Michael J. McPhaul, Michael P. Caulfield, et al.. (2019). Performance of Plasma Biomarkers and Diagnostic Panels for Nonalcoholic Steatohepatitis and Advanced Fibrosis in Patients With Type 2 Diabetes. Diabetes Care. 43(2). 290–297. 126 indexed citations
16.
Bril, Fernando, Diana Julie Leeming, M.A. Karsdal, et al.. (2019). Use of Plasma Fragments of Propeptides of Type III, V, and VI Procollagen for the Detection of Liver Fibrosis in Type 2 Diabetes. Diabetes Care. 42(7). 1348–1351. 42 indexed citations
17.
Cusi, Kenneth, Fernando Bril, Diana Barb, et al.. (2018). Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 21(4). 812–821. 137 indexed citations
18.
Bril, Fernando, Laura Millán, Srilaxmi Kalavalapalli, et al.. (2018). Use of a metabolomic approach to non‐invasively diagnose non‐alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes Obesity and Metabolism. 20(7). 1702–1709. 37 indexed citations
19.
Bril, Fernando, et al.. (2017). Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients. Diabetes Care. 41(1). 187–192. 34 indexed citations
20.
Cusi, Kenneth, Beverly Orsak, Fernando Bril, et al.. (2016). Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus. Annals of Internal Medicine. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by James M. Paik Breakdown of academic impact, for papers by Stefano Ballestri Breakdown of academic impact, for papers by Shivakumar Chitturi Breakdown of academic impact, for papers by Romina Lomonaco Breakdown of academic impact, for papers by Fabio Nascimbeni Breakdown of academic impact, for papers by M. Marietti Breakdown of academic impact, for papers by Aynur Ünalp Breakdown of academic impact, for papers by Dinan Abdelatif Breakdown of academic impact, for papers by Ester Vanni Breakdown of academic impact, for papers by Stefania Natale
Rankless by CCL
2026